To include your compound in the COVID-19 Resource Center, submit it here.

SKP-1041: Phase II data

A double-blind, crossover, U.S. Phase II trial in 67 patients with primary insomnia characterized by middle of the night awakening showed that 10, 15 and 20 mg doses of oral

Read the full 304 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE